Taysha Gene TherapiesTSHA
TSHA
About: Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
Employees: 52
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
153% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 17
68% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 19
12% more funds holding
Funds holding: 105 [Q2] → 118 (+13) [Q3]
10% more call options, than puts
Call options by funds: $55K | Put options by funds: $50K
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
5.65% less ownership
Funds ownership: 82.22% [Q2] → 76.57% (-5.65%) [Q3]
14% less capital invested
Capital invested by funds: $371M [Q2] → $318M (-$52.5M) [Q3]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$5
170%
upside
Avg. target
$6.60
257%
upside
High target
$8
332%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
Canaccord Genuity Whitney Ijem 21% 1-year accuracy 8 / 39 met price target | 332%upside $8 | Buy Maintained | 15 Nov 2024 |
Chardan Capital Geulah Livshits 17% 1-year accuracy 8 / 48 met price target | 278%upside $7 | Buy Maintained | 14 Nov 2024 |
Needham Gil Blum 21% 1-year accuracy 34 / 164 met price target | 224%upside $6 | Buy Reiterated | 14 Nov 2024 |
Cantor Fitzgerald Kristen Kluska 38% 1-year accuracy 40 / 105 met price target | 278%upside $7 | Overweight Reiterated | 14 Nov 2024 |
JMP Securities Silvan Tuerkcan 35% 1-year accuracy 18 / 51 met price target | 170%upside $5 | Market Outperform Reiterated | 12 Nov 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on December 2, 2024, the Compensation Committee of Taysha's Board of Directors granted one new employee an option to purchase 152,000 shares of the Company's common stock in connection with their employment. The stock option was granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individual entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).
Negative
Benzinga
1 month ago
Advance Auto Parts Posts Weak Results, Joins Harrow, Taysha Gene Therapies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining more than 50 points on Thursday.
Neutral
Seeking Alpha
1 month ago
Taysha Gene Therapies, Inc. (TSHA) Q3 2024 Earnings Call Transcript
Taysha Gene Therapies, Inc. (NASDAQ:TSHA ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Hayleigh Collins - Director and Head, Investor Relations Sean Nolan - Chief Executive Officer Sukumar Nagendran - President and Head, R&D Kamran Alam - Chief Financial Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Chris Raymond - Piper Sandler Whitney Ijem - Canaccord Genuity Salveen Richter - Goldman Sachs Gil Blum - Needham & Co. Maury Raycroft - Jefferies Jack Allen - Baird Joon Lee - Truist Securities Silvan Tuerkcan - Citizens JMP Keith Tapper - BMO Capital Markets Operator Greetings. And welcome to the Taysha Gene Therapies' Third Quarter 2024 Earnings Call.
Negative
Zacks Investment Research
1 month ago
Taysha Gene Therapies, Inc. (TSHA) Reports Q3 Loss, Lags Revenue Estimates
Taysha Gene Therapies, Inc. (TSHA) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.13 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update
High dose TSHA-102 was generally well tolerated with no SAEs or DLTs in two adolescent/adult patients and one pediatric patient as of data cutoff; IDMC approved continued enrollment in cohort two (high dose) across both REVEAL trials; eight patients dosed to date (low dose=4, high dose=4)
Neutral
GlobeNewsWire
1 month ago
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on November 1, 2024, the Compensation Committee of Taysha's Board of Directors granted three new employees, in the aggregate, options to purchase 157,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
1 month ago
Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress
Data from an analysis of five NHP studies showed lumbar IT administration led to widespread and consistent biodistribution of AAV9 gene therapy vectors across brain and spinal cord regions
Positive
Zacks Investment Research
2 months ago
Taysha Gene Therapies (TSHA) Upgraded to Strong Buy: Here's Why
Taysha Gene Therapies (TSHA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Positive
Seeking Alpha
2 months ago
Taysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome Data
Taysha Gene Therapies' TSHA-102 shows promising results for Rett syndrome, leveraging miRARE technology to modulate MECP2 expression, improving patients' quality of life in Phase 1/2 trials. TSHA-102's unique miRNA-responsive auto-regulatory feature ensures safe MECP2 levels, with intrathecal administration targeting CNS cells, minimizing systemic adverse effects. Despite recent stock price decline, TSHA has a solid cash runway and potential market, with key catalysts expected by late 2024 and 1H2025.
Neutral
GlobeNewsWire
2 months ago
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on October 1, 2024, the Compensation Committee of Taysha's Board of Directors granted one new employee an option to purchase 501,600 shares of the Company's common stock in connection with their employment. The stock option was granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individual entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).
Charts implemented using Lightweight Charts™